First Trust Nasdaq Pharmaceuticals ETF
$41.20−0.68 (−1.61%)
- Expense ratio
- 0.60%
- Fund size
- $1.1B
- 1Y return
- +50.8%
- Yield · Last 12 months
- 1.01%
- Holdings
- 50
- Volume · 30D
- 0.6M sh
- NAV per share
- $41.29
- 52W range
The ETF.net FTXH Grade
Score 56 of 100 sits in the B band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.FScore 21Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.AScore 76Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 68Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.BScore 66Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.AScore 74Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 80Category rank
Our read on FTXH
BMost pharma funds just size positions by market cap. FTXH screens US pharma stocks for liquidity, then ranks and weights them on value, momentum and profitability, so the biggest drugmaker isn't automatically the biggest holding.
The fund seeks returns broadly matching the price and yield of the Nasdaq US Smart PharmaceuticalsTM Index before expenses. It uses an indexing approach intended to replicate that index’s holdings and weights, targeting 95% correlation, without assuring success.
Why people hold it
- Weights follow a factor scorecard (value, momentum, profitability) rather than company size, a different recipe from the plain cap-weighted pharma funds it sits beside.ftportfolios.com
- Stays in its lane: US pharmaceutical companies, not a broad health care blend of biotech, device makers and insurers.ftportfolios.com
- Live since 2016 with a few hundred million in assets, it changes hands actively and pays distributions quarterly.
- Index replication is the whole job here, and the fund has kept close to the Nasdaq US Smart Pharmaceuticals Index it advertises.ftportfolios.com
Worth knowing
- The screen costs money: 0.60% a year, above the pharma-ETF median and well above cap-weighted rivals PPH (0.36%) and XPH (0.35%).
- About 50 names in a single sector. Patent rulings, trial results and drug-pricing headlines land with full force.
- Factor weighting cuts both ways: the lineup can look quite different from a standard cap-weighted pharma benchmark, and behave differently too.
FTXH Holdings
- Stocks
- 50
- 54%
- ABBV
Sectors
- Health Care100.0%
Geography
- United States96.58%
- Ireland2.88%
- United Kingdom0.54%
FTXH Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | FTXH |
|---|---|
| Year to date | +27.7% |
| 1 month | −0.9% |
| 3 months | +17.2% |
| 1 year | +50.8% |
| 3 years | +19.1% |
| 5 years | +11.9% |
| 10 years | +8.8% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | FTXH |
|---|---|---|
| 2026 YTD | +27.7% | |
| 2025 | +24.2% | |
| 2024 | +3.0% | |
| 2023 | −1.4% | |
| 2022 | +2.5% | |
| 2021 | +6.1% | |
| 2020 | +11.7% |
FTXH in the news
ETF.net Research hasn’t filed on FTXH yet — coverage lands here as it’s written.
FTXH Dividends
- 1.01%
- $0.42
- $0.09 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Jun 25, 2026 | Jun 30, 2026 | $0.09 |
| Mar 26, 2026 | Mar 31, 2026 | $0.06 |
| Dec 12, 2025 | Dec 31, 2025 | $0.13 |
| Sep 25, 2025 | Sep 30, 2025 | $0.15 |
| Jun 26, 2025 | Jun 30, 2025 | $0.09 |
| Mar 27, 2025 | Mar 31, 2025 | $0.10 |
| Dec 13, 2024 | Dec 31, 2024 | $0.13 |
| Sep 26, 2024 | Sep 30, 2024 | $0.12 |
| Jun 27, 2024 | Jun 28, 2024 | $0.13 |
| Mar 21, 2024 | Mar 28, 2024 | $0.07 |
| Dec 22, 2023 | Dec 29, 2023 | $0.12 |
| Sep 22, 2023 | Sep 29, 2023 | $0.07 |
FTXH Risk
- 14.7%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.84
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −19.5%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.46
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
FTXH Cost
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
7 of the 9 Pharma & Therapeutics funds charge less.